This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.
Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program
by Zacks Equity Research
Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.
Company News for May 19, 2021
by Zacks Equity Research
Companies In The News Are: WMT, TWLO, WFC, BRK.B, BMY, AGEN
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
by Zacks Equity Research
Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.
Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate
by Zacks Equity Research
Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.
Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.
Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.70, marking a +0.4% move from the previous day.
ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.
Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.
Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.
Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.
Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider Q1 loss on increased R&D expenses.
bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.
Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales
by Zacks Equity Research
Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca. Stock up.
Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.
Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.
Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Merck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts Vaccines
by Kinjel Shah
Merck (MRK) misses Q1 estimates for earnings and sales. Stock down in pre-market.
Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline
by Zacks Equity Research
Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.
Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of -3.33% and -0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Here is Why Growth Investors Should Buy Bristol Myers (BMY) Now
by Zacks Equity Research
Bristol Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.